title: Bifeprunox vs Placebo for Schizophrenia.
authors.affiliation: Medical School, University of Nottingham, Nottingham, UK; mzyac9@nottingham.ac.uk.
authors.forename: Arka
authors.initials: A
authors.lastname: Chattopadhyay
authors.affiliation: Institute of Mental Health, University of Nottingham, Nottingham, UK.
authors.forename: Stephen
authors.initials: S
authors.lastname: Frey
authors.affiliation: Institute of Mental Health, University of Nottingham, Nottingham, UK.
authors.forename: Ghiselle
authors.initials: G
authors.lastname: Green
authors.affiliation: Institute of Mental Health, University of Nottingham, Nottingham, UK.
authors.forename: Alexandra
authors.initials: A
authors.lastname: Harkness
authors.affiliation: Institute of Mental Health, University of Nottingham, Nottingham, UK.
authors.forename: Alice
authors.initials: A
authors.lastname: McDermott
authors.affiliation: Institute of Mental Health, University of Nottingham, Nottingham, UK.
authors.forename: Anna
authors.initials: A
authors.lastname: Yates
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001583:Benzoxazoles / Q000627:therapeutic use*; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001583:Benzoxazoles; D010879:Piperazines; C509981:bifeprunox